603882:SSEGuangzhou Kingmed Diagnostics Group Co. Ltd. Class A Analysis
Data as of 2026-03-12 - not real-time
CN¥28.29
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The stock trades at 28.29 CNY, below its 20‑day (30.08), 50‑day (31.06) and 200‑day (29.97) moving averages, with a bearish MACD histogram and an RSI of 37, signalling short‑term momentum weakness. Volume is on a decreasing trend and price sits just above the calculated support at 27.60 CNY, while resistance is near 32.47 CNY.
Fundamental outlook: Revenue declined 11% YoY and the company posted a –9% profit margin, resulting in a negative trailing EPS. Nonetheless, the forward P/E of 23.6 is below the industry average of 26.5 and the DCF‑derived fair value of ~36.6 CNY points to a potential upside. The dividend yield appears generous at 6.15% but the payout ratio exceeds 250%, questioning sustainability. The balance sheet is strong with cash over four times debt and an ultra‑low beta (~0.03), yet 30‑day volatility is high at 35% and the max drawdown exceeds 25%.
Fundamental outlook: Revenue declined 11% YoY and the company posted a –9% profit margin, resulting in a negative trailing EPS. Nonetheless, the forward P/E of 23.6 is below the industry average of 26.5 and the DCF‑derived fair value of ~36.6 CNY points to a potential upside. The dividend yield appears generous at 6.15% but the payout ratio exceeds 250%, questioning sustainability. The balance sheet is strong with cash over four times debt and an ultra‑low beta (~0.03), yet 30‑day volatility is high at 35% and the max drawdown exceeds 25%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below all major moving averages
- Bearish MACD and low RSI
- Proximity to technical support level
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- DCF fair value ~36.6 CNY vs current 28.3 CNY
- Forward P/E below industry average
- Strong cash position and low leverage
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Potential earnings turnaround after revenue slump
- Undervalued relative to intrinsic valuation
- Sustained high dividend yield if payout ratio improves
Key Metrics & Analysis
Financial Health
Revenue Growth-11.30%
Profit Margin-9.08%
P/E Ratio23.6
ROE-7.85%
ROA-2.30%
Debt/Equity11.31
P/B Ratio1.9
Op. Cash FlowCN¥1.3B
Free Cash FlowCN¥1.1B
Industry P/E26.5
Technical Analysis
TrendNeutral
RSI37.3
SupportCN¥27.60
ResistanceCN¥32.47
MA 20CN¥30.08
MA 50CN¥31.06
MA 200CN¥29.97
MACDBearish
VolumeDecreasing
Fear & Greed Index75.3
Valuation
Fair ValueCN¥36.58
GradeUndervalued
TypeValue
Dividend Yield6.15%
Risk Assessment
Beta0.03
Volatility34.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.